The Lagos State Government has urged artisans to adopt a proactive approach to safety and foster a culture of safety within ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Ahead of the market opening on Wednesday, Axis Direct picked five stocks that can generate profits in 5 to 15 days. These are ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Nagaraj Shetti, Technical Research Analyst at HDFC Securities, believes Monday's pattern could be considered as a High Wave, ...

Gilead Sciences collaborates with Indian companies to produce affordable generic versions of its HIV prevention therapy, ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Nifty moved in a tight range of 82 points, and ended slightly below the psychologically crucial level of 15,700. NEW DELHI: ...

Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.